Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association

Authors, Journal, Affiliations, Type, DOI

• James E. Tisdale, PharmD (Chair) — Purdue University College of Pharmacy / Indiana University
• Mina K. Chung, MD (Vice Chair) — Cleveland Clinic
• Kristen B. Campbell, PharmD — Duke University Medical Center
• Muhammad Hammadah, MD — Emory University School of Medicine
• Jose A. Joglar, MD — University of Texas Southwestern Medical Center
• Jacinthe Leclerc, RN, PhD — Université du Québec à Trois-Rivières
• Bharath Rajagopalan, MD — Prairie Heart Institute
• Circulation. 2020;142:e214–e233
• Type: AHA Scientific Statement (systematic literature review — MEDLINE/PubMed, Cochrane, Embase, ClinicalTrials.gov)
• DOI: 10.1161/CIR.0000000000000905

Overview

Many widely used medications can cause or exacerbate a broad spectrum of cardiac arrhythmias, spanning from bradyarrhythmias and supraventricular arrhythmias to ventricular arrhythmias and drug-induced Brugada syndrome. Torsades de pointes (TdP) — caused predominantly by IKr-blocking drugs — is the most clinically serious drug-induced arrhythmia, with >200 drugs retaining market availability despite TdP potential. Risk factors for TdP are well-defined, and approximately 30% of patients who develop drug-induced QT prolongation carry a latent LQTS mutation. Management principles centre on drug discontinuation, modifiable risk factor correction, and arrhythmia-specific treatment; prevention requires heightened clinical awareness and QTc monitoring.

Keywords

AHA Scientific Statements, atrial fibrillation, bradycardia, Brugada syndrome, tachycardia, atrioventricular nodal reentry tachycardia, ventricular tachycardia, torsades de pointes

Key Takeaways

Drug-Induced Bradyarrhythmias

• Sinus node dysfunction and AV block are the two categories; mechanisms include inhibition of automaticity, slowing of conduction, and prolongation of repolarization in the sinus/AV node.
• Key drug classes: β-blockers (0.6–25%), calcium channel blockers (diltiazem 4.2–16%, verapamil 0–11%), digoxin (0–7%), amiodarone (3–20%), ivabradine (3.7–15.7% via If channel inhibition), fingolimod (0.5–3.7% via S1P1 receptor modulation), acetylcholinesterase inhibitors (donepezil 0.6–48%).
• ~50% of patients with drug-induced bradyarrhythmia experience persistence or recurrence after drug discontinuation and may still require permanent pacemaker.
• Management: dose reduction/discontinuation; atropine 0.5 mg IV (not in heart transplant patients — may paradoxically worsen block); isoproterenol, dopamine, or epinephrine if haemodynamically unstable; temporary pacing if refractory.
• Overdose: Glucagon 3–10 mg IV bolus then 3–5 mg/h for β-blocker/CCB overdose; high-dose insulin (1 unit/kg bolus + 0.5 unit/kg/h infusion) is an option in refractory AV block.

Drug-Induced Atrial Fibrillation / Atrial Flutter

• Large catalog of causative agents: adenosine (1–12%), anticancer agents (tyrosine kinase inhibitors 3.3–6.5%; anthracyclines 1.4–13.8%; alkylating agents up to 15.5%; trastuzumab 1.2–19.9%), antipsychotics (chlorpromazine OR 1.96, clozapine OR 2.81), alcohol (pooled OR/RR 1.51), dobutamine (0–18%), bronchodilators (albuterol, theophylline), bisphosphonates (alendronate OR 1.86–1.97), NSAIDs/COX-2 inhibitors.
• Mechanisms vary: catecholaminergic augmentation (stimulants), shortened atrial ERP (alcohol, bisphosphonates, adenosine), parasympathetic activation (alcohol), sodium channel blockade → AFL (flecainide, propafenone).
• Class IC antiarrhythmics can cause 1:1 AFL with wide QRS if AV nodal blocking drugs are not co-prescribed.
• Amiodarone may precipitate AF via amiodarone-induced thyrotoxicosis.
• Management: Discontinue offending agent; many patients self-convert. Rate control with AV nodal blocking agents. If AF ≥48 h or unknown duration: TOE to exclude LAA thrombus OR ≥3 weeks therapeutic anticoagulation before cardioversion. Haemodynamically unstable: urgent cardioversion.

Drug-Induced Atrial Tachycardia

• Multifocal AT most commonly linked to theophylline (serum level >20 μg/mL), β-agonists, and hypomagnesaemia; digoxin toxicity causes paroxysmal AT with AV block via intracellular Ca²⁺ overload and vagomimetic activity.
• Risk factors for digoxin-induced AT: digoxin level >2 ng/mL, renal disease, hypomagnesaemia, drug interactions (amiodarone, verapamil, quinidine).
• Management: rate control, antiarrhythmics (flecainide, propafenone, sotalol, amiodarone), magnesium for multifocal AT; digoxin immune antibody fragments for digoxin toxicity.

Drug-Induced AVNRT

• Requires anatomical substrate (dual AV nodal pathways); drugs that enhance AV nodal conduction or produce premature extrastimuli trigger AVNRT in susceptible individuals.
• Causative drugs: albuterol (0–21%), dobutamine (0–12%), caffeine, theophylline, methylphenidate, clozapine, methylprednisolone.
• Management: discontinue offending drug; vagal maneuvers + IV adenosine as first-line; IV diltiazem/verapamil/β-blockers if adenosine ineffective; catheter ablation of slow pathway has high long-term success.

Drug-Induced Monomorphic Ventricular Tachycardia

• Mechanisms: sodium channel inhibition (Class IC agents) → reduced conduction velocity + increased reentry; sodium channel activation (aconite alkaloids) → increased automaticity; intracellular Ca²⁺ overload (digoxin, theophylline) → triggered activity; coronary steal (adenosine, dipyridamole); β₂ stimulation (dobutamine, epinephrine).
• CAST trial (critical): Class IC agents (flecainide, encainide) increased mortality in patients with structural heart disease post-MI — Class IC antiarrhythmics are contraindicated in prior MI or cardiomyopathy.
• Therapeutic windows: digoxin <2 ng/mL; theophylline <20 μg/mL; avoid in hypomagnesaemia/hypokalaemia.
• Management: haemodynamically unstable → synchronized cardioversion; stable → IV amiodarone, lidocaine, or procainamide; lipid emulsion for bupivacaine-induced VT.

Drug-Induced Brugada Syndrome

• Defined as normal pretreatment ECG developing type 1 Brugada pattern after drug exposure; underlying genetic substrate (SCN5A or other) often present but previously silent.
• Common culprit drugs:
  • Antiarrhythmics: ajmaline (39–48.2% in high-pretest population), pilsicainide (11–18% VA risk), flecainide, procainamide, propafenone — all via INa blockade.
  • Tricyclic antidepressants: amitriptyline, desipramine, imipramine, nortriptyline (2.3–15.3% in overdose).
  • Anesthetics: bupivacaine, procaine, propofol.
  • Others: alcohol (ICa,L blockade), cocaine, lithium, loxapine, oxcarbazepine.
• Full list of drugs to avoid in BrS: brugadadrugs.org
• Drug-induced BrS often asymptomatic; syncope/VT/VF onset ranges weeks to years after initiation; fever is a precipitant.
• SCD risk from drug-induced BrS: ~0.08%/year — significantly lower than spontaneous Brugada syndrome.
• Many patients with drug-induced BrS also have spontaneous type 1 ECG on ambulatory monitoring — ambulatory rhythm monitoring required to exclude latent BrS after offending drug is stopped.
• Management: Discontinue offending agent; screen for latent BrS with ambulatory ECG; cardioversion/defibrillation or amiodarone for VT/VF; procainamide contraindicated (potentiates sodium channel inhibition); ICD if prior cardiac arrest, sustained VT, or syncope with spontaneous type 1 ECG.

Torsades de Pointes (Drug-Induced)

• TdP is polymorphic VT associated with QT prolongation — most common cause is drugs (acquired LQTS); >200 drugs remain on the market with TdP potential.
• Primary mechanism: IKr inhibition → action potential duration prolongation → early afterdepolarizations (EADs) → TdP via phase 2 reentry. Some drugs also augment late sodium current (INa-L): dofetilide, ibutilide, d-sotalol, thioridazine, erythromycin.
• Repolarization reserve theory: Repolarization is modulated by multiple partially redundant mechanisms (IKr, IKs, INa-L); when one is perturbed (e.g., congenital mutation in IKr), normal QTc may be maintained. Introduction of an IKr-inhibiting drug depletes repolarization reserve and uncovers QT prolongation/TdP risk.
• ~30% of patients with drug-induced QT prolongation carry pathogenic variants in one of the 5 major LQTS genes — drug-induced TdP often unmasks subclinical congenital LQTS.
• Key QT-prolonging drugs known to cause TdP:
  • Antiarrhythmics: amiodarone (0.7–1.5%), dofetilide (1–10%), quinidine (2–12%), sotalol (0.2–23.6%), ibutilide (1.2–11.5%), procainamide (0.3–6%)
  • Antibiotics: azithromycin (0.97%), erythromycin (0.4%), levofloxacin (0.2%), clarithromycin, moxifloxacin
  • Antipsychotics: haloperidol (3.6%), chlorpromazine, thioridazine, pimozide
  • Antimalarials: chloroquine, hydroxychloroquine, halofantrine
  • Antidepressants (SSRI): citalopram, escitalopram
  • Antiemetics: domperidone, droperidol, ondansetron
  • Opioids: methadone
  • Antifungals: fluconazole, pentamidine (up to 21%)
  • Anticancer: arsenic trioxide, vandetanib, oxaliplatin
• Amiodarone notably does not increase transmural dispersion of repolarization — partly explaining its lower TdP incidence vs. quinidine/sotalol.
• Risk factors for TdP: QTc >500 ms or QTc increase ≥60 ms from baseline; female sex; age >65; bradycardia; acute MI; hypokalaemia; hypomagnesaemia; hypocalcaemia; HFrEF; ≥2 concurrent QT-prolonging drugs; prior drug-induced TdP; pharmacokinetic drug interactions; renal/hepatic impairment with renally/hepatically eliminated drugs.
• Prevention: Maintain K⁺ >4.0 mEq/L and Mg²⁺ >2.0 mg/dL; avoid QT drug combinations; adjust doses in organ dysfunction; obtain baseline ECG.
• Monitoring: QTc should be maintained <500 ms (without QRS prolongation); daily ECG in hospitalised patients on antiarrhythmic drugs with TdP risk; 12-lead ECG every 3–6 months for long-term QT-prolonging therapy; for methadone: ECG at admission, within 30 days if risk factors, annually or when dose >120 mg/day.
• Management: Discontinue QT-prolonging drugs; correct electrolytes; IV magnesium 1–2 g (may repeat) — terminates haemodynamically stable TdP regardless of serum Mg level, possibly via Ca²⁺ channel inhibition suppressing EADs; for recurrent TdP with bradycardia: overdrive pacing or isoproterenol; oral mexiletine 200–450 mg/day for refractory TdP; defibrillation for haemodynamically unstable TdP (synchronisation may be impossible in polymorphic VT).

QT Interval Shortening

• Short-QT syndrome (QTc ≤360 ms) is rare; no documented ventricular proarrhythmia from QT-shortening drugs reported in literature.
• Drugs that may shorten QT: antiepileptics (primidone, lamotrigine, phenytoin, rufinamide), digitalis glycosides, Class IB antiarrhythmics (lidocaine, mexiletine), potassium rectifier agents (pinacidil, levcromakalim, nicorandil).
• No recommendation to avoid these in SQTS patients, but prudent caution warranted if drug is not absolutely necessary.

Limitations of the Document

• Incidences of drug-induced arrhythmias are drawn from heterogeneous sources (RCTs, observational studies, case reports); evidence quality varies substantially.
• Many incidences are based on case reports only (marked with * in tables) — causality difficult to confirm.
• COVID-19 drug data (hydroxychloroquine/azithromycin) is preliminary (early 2020 pandemic data only).
• General genetic screening for drug-induced TdP risk prediction is not currently recommended despite the 30% LQTS variant finding — no validated pre-prescription genetic screening protocol exists.

Key Concepts Mentioned

• concepts/Torsades-de-Pointes — central topic; drug-induced TdP via IKr inhibition, repolarization reserve, risk factors, and management
• concepts/Drug-Induced-Arrhythmia — comprehensive overview of all seven drug-induced arrhythmia types
• concepts/Cardiac-Action-Potential — mechanism basis for IKr/INa-L/Ito drug effects

Key Entities Mentioned

• entities/Brugada-Syndrome — drug-induced unmasking; sodium channel blocker drug list; 0.08%/year SCD risk
• entities/Long-QT-Syndrome — ~30% of drug-induced TdP patients carry latent LQTS variants; repolarization reserve concept
• entities/Atrial-Fibrillation — comprehensive drug-induced AF catalog
• entities/KCNH2 — IKr as the primary target of TdP-inducing drugs

Wiki Pages Updated

• Created: wiki/sources/drug-arrhythmia-aha-2020.md
• Created: wiki/concepts/Drug-Induced-Arrhythmia.md
• Updated: wiki/concepts/Torsades-de-Pointes.md
• Updated: wiki/entities/Brugada-Syndrome.md
• Updated: wiki/entities/Long-QT-Syndrome.md
• Updated: wiki/entities/Atrial-Fibrillation.md
• Updated: wiki/wikiindex.md
• Updated: wiki/sourceindex.md